Antidepressants and falls in the elderly

Drugs and Aging

Volumn 26, Issue 5, 2009, Pages 381-394

  Darowski, Adam ^a   Chambers, Sally Ann C F ^b   Chambers, David J ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; ISOCARBOXAZID; LOFEPRAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG;

AGING; ATRIOVENTRICULAR BLOCK; BALANCE IMPAIRMENT; BODY POSTURE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DAYTIME SOMNOLENCE; DEPRESSION; DIZZINESS; DROWSINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FRACTURE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HIP FRACTURE; HUMAN; INSOMNIA; MOTOR DYSFUNCTION; NOCTURIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; TACHYCARDIA;

ACCIDENTAL FALLS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; HUMANS; RISK FACTORS; SLEEP;

EID: 68149091957     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-200926050-00002     Document Type: Review

References (86)

1. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy and safety of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997; 46: 191-217
2. Whooley MA, Kip KE, Cauley JA, et al. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 484-90
3. Turcu A, Toubin S, Mourey F, et al. Falls and depression in older people. Gerontology 2004; 50: 303-8
4. Asplund R, Johansson S, Henriksson S, et al. Nocturia, depression and antidepressant medication. BJU Int 2005; 95 (6): 820-3
5. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998; 339: 875-82
6. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor anti-depressants and the risk of hip fracture. Am J Epidemiol 2003; 158: 77-84
7. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: 1. Psychotropic drugs. J Am Geriatr Soc 1999; 37: 30-9
8. Liu B, Anderson G, Mittmann N, et al. Use of selected serotonin reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351: 1303-7
9. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006; 17: 807-16
10. Kelly KD, Pickett W, Yiannakoulias N, et al. Medication use and falls in community-dwelling older persons. Age Ageing 2003; 32: 503-9
11. Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 1991; 151: 754-6
12. Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross-sectional study. BMJ 2003; 327: 712-7
13. Ebly EM, Hogan DB, Fung TS. Potential adverse outcomes of psychotropic and narcotic drug use in Canadian seniors. J Clin Epidemiol 1997; 50 (7): 857-63
14. Ensrud KE, Blackwell TL, Mangione CM, et al. Central nervous system: active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50: 1629-37
15. Arfken CL, Wilson JG, Aronson SM. Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr 2001; 13 (1): 85-91
16. Lewis CE, Ewing SK, Taylor BC, et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007; 22: 211-9
17. Kallin K, Gustafson Y, Sandman P, et al. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 2004; 16 (4): 270-6
18. Souchet E, Lapeyre-Mestre M, Montastruc JL. Drug related falls: a study in the French Pharmacovigilance database. Pharmacoepidemiol Drug Saf 2005; 14: 11-6
19. Vassallo M, Sharma JC, Allen SC. Characteristics of single fallers and recurrent fallers among hospital inpatients. Gerontology 2002; 48: 147-50
20. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984; 230: 94-102
21. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114: 559-65
22. Stage KB, Kragh-Sjorensen P. Age-related adverse drug reactions to clomipramine. Acta Psychiatr Scand 2002; 105: 55-9
23. Robinson DS, Nies A, Corcella J, et al. Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients. J Clin Psychiatry 1982; 43: 8-15
24. Biswas P, Wilton LV, Shakir SA. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J Psychopharmacol 2003; 17: 121-6
25. Muldoon C. The safety and tolerability of citalopram. Int Clin Psychopharmacol 1996; 11 Suppl. 1: 35-40
26. Barak Y, Swartz M, Levy D, et al. Age-related differences in the side-effect profile of citalopram. Prog Neuropsycho-pharmacol Bio Psychiatry 2003; 27: 545-8
27. Grimsley SR, Jann MW. Paroxetine sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11 (11): 930-57
28. Dechant KL, Clissold SP. Paroxetine: a review. Drugs 1991; 41 (2): 225-53
29. Trick L, Stanley N, Rigney U, et al. A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice. J Psychopharmacol 2004; 18 (2): 205-14
30. Brunnauer A, Laux G, Geiger E, et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 2006; 67 (11): 1776-81
31. Krystal AD, Thase ME, Tucker VL, et al. Bupropion HCl and sleep in patients with depression. Curr Psychiatry Rev 2007; 3 (2): 123-8
32. Asplund R, Henriksson S, Johansson S, et al. Nocturia and depression. BJU Int 2004; 93 (9): 253-6
33. Teo JSH, Briffa NK, Devine A, et al. Do sleep problems or urinary incontinence predict falls in elderly women? Aust J Physiother 2006; 52: 19-24
34. Asplund R, Johansson S, Svante H, et al. Nocturia, depression and antidepressant medication. BJU Int 2005; 95: 820-3
35. Goldman SE, Stone KL, Ancoli-Israel S. Poor sleep is associated with poorer physical performance and greater functional limitations in older women. Sleep 2007; 30 (10): 1317-24
36. Ensrud KE, Blackwell TL, Ancoli-Israel S, et al. Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. J Am Geriatr Soc 2006; 54 (10): 1508-15
37. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20 (8): 533-59
38. Li X, Hamdy R, Sandborn W, et al. Long-term effects of antidepressants on balance, equilibrium and postural reflexes. Psychiatry Res 1996; 63: 191-6
39. Fairweather DB, Kerr JS, Harrison DA, et al. A double blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients. Human Psychopharmacol 1993; 8: 41-7
40. Laghrissi-Thode F, Pollock BG, Miller M, et al. Comparative effects of sertraline and nortriptyline on body sway in older depressed patients. Am J Geriatr Psychiatry 1995; 3: 228-37
41. Mamo DC, Pollock MD, Mulsani B, et al. Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am J Geriatr Psychiatry 2002; 10 (2): 199-205
42. Draganich LF, Zacny J, Klafta J, et al. The effects of anti-depressants on obstructed and unobstructed gait in healthy elderly people. J Gerontol A Biol Sci Med Sci 2001; 56 (1): M36-41
43. Heitterachi E, Lord SR, Meyerkort P, et al. Blood pressure changes on upright tilting predict falls in older people. Age Ageing 2002; 31: 181-6
44. Graafmans WC, Ooms ME, Hofstee HMA, et al. Falls in the elderly: A prospective study of risk factors and risk profiles. Am J Epidemiol 1996; 142 (11): 1129-36
45. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005; 30: 173-8
46. Ooi W, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. Am J Med 2000; 108: 106-11
47. Hayes JR, Born GF, Rosenbaum AH. Incidence of orthostatic hypotension in patients with primary affective dis-orders treated with tricyclic antidepressants. Mayo Clin Proc 1977; 52: 509-12
48. Glassman AH, Bigger JT, Giardina EV, et al. Clinical characteristics of imipramine induced orthostatic hypotension. Lancet 1979; 1 (8114): 468-72
49. Glassman AH, Bigger JT. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1982; 38: 815-20
50. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol 1998; 13 Suppl. 5:S25-30
51. Glassman AH, Johnson LL, Giardina EV, et al. The use of imipramine in depressed patients with congestive cardiac failure. JAMA 1983; 250 (15): 1997-2001
52. Roose SP, Glassman AH, Giardina EV, et al. Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986; 256 (23): 3253-7
53. Miller MD, Pollock BG, Rifai AH, et al. Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Geriatr Psychiatry Neurol 1991; 4: 226-30
54. Farid FF, Wenger TL, Tsai SY, et al. Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants. J Clin Psychiatry 1983; 44 (5 Pt 2): 170-3
55. Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148 (4): 512-6
56. Moller M, Thayssen P, Kragh-Sorensen P, et al. Mianserin: cardiovascular effects in elderly patients. Psychopharmacology 1983; 80: 174-7
57. Coupland NJ, Wilson SJ, Potokar JP, et al. A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. Int Clin Psychopharmacol 1995; 10: 229-38
58. Rabkin JG, Quitkin M, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: part 1. A comparative study. J Clin Psychopharmacol 1984; 4: 270-8
59. Stage KB. Orthostatic side effects of clomipramine and moclobemide during treatment for depression. Nord J Psychiatry 2005; 59: 298-301
60. Koczkas C, Holm A, Karlsson A, et al. Moclobemide and clomipramine in endogenous depression: a randomised clinical trial. Acta Psychiatr Scand 1989; 79: 523-9
61. Delini-Stula A, Baier D, Kohnen R, et al. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor: results of the drug utilization observation studies. Pharmacopsychiatry 1999; 32: 61-7
62. Joo BA, Lenze EJ, Mulsant BH, et al. Risk factors for falls during treatment of late life depression. J Clin Psychiatry 2002; 63 (10): 936-41
63. Andrews C, Pinner G. Postural hypotension induced by paroxetine. BMJ 1998; 316: 595
64. Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late life depression.AmJGeriatr Psychiatry 2006; 14(9): 796-802
65. Kok R, Nolen W, Heeren T. Cardiovascular changes associated with venlafaxine in the treatment of late life depression [letter]. Am J Geriatr Psychiatry 2007; 15 (8): 725
66. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007; 30 (5): 437-55
67. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008; 28 (1): 32-8
68. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997; 7 Suppl. 1: S37-47
69. Versiani M, Amin M, Chouinard G. Double-blind, Placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20: 28-34
70. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58-77
71. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns. Curr Pharm Des 2004; 10: 2463-75
72. Roose SP, Glassman AH, Giardina EV, et al. Tricyclic anti-depressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987; 44 (3): 273-5
73. Gambassi G, Incalzi R. Atrioventricular blocks associated with citalopram. Am J Geriatr Psychiatry 2005; 13 (10): 918-9
74. Gardner SF, Rutherford WF, Munger MA, et al. Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann Emerg Med 1991; 20: 194-7
75. McAnally LE, Threlkeld KR, Dreyling CA. Case report of a syncopal episode associated with fluoxetine. Ann Pharmacother 1992; 26 (9): 1090-1
76. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51 (9): 385-6
77. Feder R. Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry 1991; 52 (3): 139
78. Cherin P, Colvez A, Deville de Perriere GD, et al. Risk of syncope in the elderly and consumption of drugs: a case control study. J Clin Epidemiol 1997; 50 (3): 313-20
79. Sleeper R, Bond CA, Rojas-Fernandez C. Psychotropic drugs and falls: new evidence pertaining to serotonin reuptake inhibitors. Pharmacotherapy 2000; 20: 308-17
80. Saag K. Mend the mind but mind the bones. Arch Int Med 2007; 167: 1231-2
81. Williams LJ, Henry MJ, Berk M, et al. SSRI use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008; 23 (2): 84-7
82. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167 (12): 1246-51
83. Diem SJ, Blackwell TL, Stone KL, et al. Use of anti-depressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167 (12): 1240-5
84. Demyttenaere K, Jaspers L. Bupropion and SSRI-induced side effects. J Psychopharmacol 2008; 22 (7): 792-804
85. Beyens MN, Guy C, Mounier G, et al. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf 2008; 31 (11): 1017-26
86. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20 (8): 533-59